![share_log](https://pubimg.futunn.com/201912120187256955015721ae9.jpg?imageMogr2/thumbnail/76x76!/ignore-error/1/format/webp)
Altimmune | 10-K: FY2023 Annual Report
Altimmune | 10-K: FY2023 Annual Report
Altimmune | 10-K:2023財年年報
牛牛AI助理已提取核心訊息
Altimmune, a clinical stage biopharmaceutical company, has not generated revenue from product sales but has historically relied on government and foundation grants. In 2023, the company reported a slight increase in net loss to $88.4 million, up from $84.7 million in 2022. Research and development expenses decreased by 7% to $65.8 million, primarily due to reduced costs in pemvidutide development for obesity and metabolic dysfunction-associated steatohepatitis (MASH). General and administrative expenses rose by 6% to $18.1 million. The company also recorded a non-cash impairment charge of $12.4 million for the discontinued HepTcell program. Altimmune's cash position remains strong with $197.9 million in cash, cash equivalents, and short-term investments as of December 31, 2023, which is expected to fund operations for at least twelve months. The company's lead...Show More
Altimmune, a clinical stage biopharmaceutical company, has not generated revenue from product sales but has historically relied on government and foundation grants. In 2023, the company reported a slight increase in net loss to $88.4 million, up from $84.7 million in 2022. Research and development expenses decreased by 7% to $65.8 million, primarily due to reduced costs in pemvidutide development for obesity and metabolic dysfunction-associated steatohepatitis (MASH). General and administrative expenses rose by 6% to $18.1 million. The company also recorded a non-cash impairment charge of $12.4 million for the discontinued HepTcell program. Altimmune's cash position remains strong with $197.9 million in cash, cash equivalents, and short-term investments as of December 31, 2023, which is expected to fund operations for at least twelve months. The company's lead product candidate, pemvidutide, received FDA fast track designation for MASH treatment and is undergoing a Phase 2b trial. Top-line results from the trial are expected in Q1 2025. However, development of HepTcell for chronic hepatitis B was halted due to insufficient trial results. Altimmune plans to continue investing in research and development, focusing on pemvidutide and other clinical and preclinical candidates.
Altimmune,一家處於臨床階段的生物製藥公司,尚未從產品銷售中獲得營業收入,但歷史上一直依賴政府和基金會的撥款。2023年,公司的淨虧損略有增加,達到8840萬美元,比2022年的8470萬美元略有增加。研發費用下降了7%,達到6580萬美元,主要是由於肥胖症和代謝功能障礙相關脂肪性肝炎(MASH)的Pemvidutide開發成本降低。總務和管理費用上升了6%,達到1810萬美元。該公司還因終止HepTcell項目而記錄了一項非現金減值費用1240萬美元。截至2023年12月31日,Altimmune的現金、現金等價物和短期投資達到19790萬美元,預計可爲至少12個月的運營提供資金支持...展開全部
Altimmune,一家處於臨床階段的生物製藥公司,尚未從產品銷售中獲得營業收入,但歷史上一直依賴政府和基金會的撥款。2023年,公司的淨虧損略有增加,達到8840萬美元,比2022年的8470萬美元略有增加。研發費用下降了7%,達到6580萬美元,主要是由於肥胖症和代謝功能障礙相關脂肪性肝炎(MASH)的Pemvidutide開發成本降低。總務和管理費用上升了6%,達到1810萬美元。該公司還因終止HepTcell項目而記錄了一項非現金減值費用1240萬美元。截至2023年12月31日,Altimmune的現金、現金等價物和短期投資達到19790萬美元,預計可爲至少12個月的運營提供資金支持。該公司的主要產品候選藥物Pemvidutide已獲得FDA的MASH治療快速通道認可,並正在進行第20期臨床試驗。預計該試驗的頂線結果將於2025年第一季度公佈。然而,由於試驗結果不足,HepTcell用於慢性乙型肝炎的開發被中止。Altimmune計劃繼續投資於研究和開發,重點關注Pemvidutide和其他臨床和臨床前候選物。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了